Genovis Acquires KPL
We are expanding our enzyme platform with a proprietary portfolio of precision proteases for protein analysis!
We have entered into an agreement to acquire, and completed the acquisition of, 100 percent of the shares in KPL ApS (“KPL”), a Denmark‑based life science tools company with a proprietary portfolio of precision enzymes (proteases), both commercialized and in development, for mass spectrometry‑based protein analysis across academic research, diagnostics and drug development. The acquisition expands Genovis’ enzyme platform into a complementary, fast-growing, high‑usage segment of protein analysis.
By adding KPL’s proprietary protease portfolio alongside SmartEnzymes™, Genovis strengthens its coverage of LC‑MS‑based proteomics, creating tangible value through more reliable, scalable, and integrated workflows. The total consideration consisted of an upfront payment of MDKK 30.5, settled partly in cash and partly through 1,395,587 newly issued Genovis shares at a subscription price of SEK 20.03 per share (the “Consideration Shares”), issued pursuant to the authorisation granted by the Annual General Meeting on 18 May 2026, and a variable, sales-based earn-out, payable in 2030.
Genovis CEO Fredrik Olsson commented:
“We are delighted to welcome the KPL team to Genovis. They have built an impressive company — with a growing customer base and a proprietary enzyme platform that is genuinely differentiated. We look forward to making KPL’s unique portfolio available to significantly more researchers through our global commercial platform, and equally to the expertise and innovative capabilities they bring to Genovis as we continue to develop the next generation of enzyme tools.”
CEO and Co-founder of KPL, Tanveer Singh Batth (PhD), commented:
“My co‑founders and I are very pleased to become part of Genovis. Having worked with the Genovis team previously, we know firsthand that they share our commitment to developing high-quality enzyme tools for the research community. Our products have gained strong traction, and joining Genovis is the right step to support our continued development. We look forward to benefiting from Genovis’ commercial platform and industry reach, which will allow us to focus on further developing our protease portfolio and supporting customers more effectively.”